DiscoverA4LI H-SPAN Podcast
A4LI H-SPAN Podcast
Claim Ownership

A4LI H-SPAN Podcast

Author: The Alliance For Longevity Initiatives

Subscribed: 2Played: 10
Share

Description

Our Podcast highlights notable figures within the longevity field. The goal is to create social and political action around the issues of combating age-related chronic conditions and increasing our number of healthy, disease-free years!

28 Episodes
Reverse
This week on H-SPAN, we sat down with Brian Cole, a state representative from New Hampshire who has recently announced his candidacy for the U.S. House of Representatives.In this episode, we discuss Brian’s introduction to politics, what the government can do to advance aging research, and how New Hampshire is poised to emerge as the next state to embrace longevity science.
This week on H-SPAN, we are joined by Dr. Andrew Brack, Program Manager at the Advanced Research Projects Agency for Health (ARPA-H)In this episode, we discuss Andrew's unique journey that led him to the longevity space, what PROSPR is doing to move the industry forward, and how ARPA-H can serve as a catalyst for healthspan innovation.
This week on H-Span, we are joined by Dr. Irina and Michael Conboy of the Department of Bioengineering at the University of California BerkeleyIn this episode, we discuss their breakthrough work with therapeutic plasma exchange, the recent A4LI D.C. Summit, and how young scientists can get involved in the longevity space.
This week on H-Span, we are joined by Niklas Anzinger, Co-Founder and CEO of Infinita City.In this episode, Niklas shares his fascinating journey into the world of longevity, offers a behind-the-scenes look at what Infinita is building in Próspera, and explores the potential for creating a Próspera-like community in the United States.
This week on H-Span, we are joined by Michael Ringel, PhD, Chief Operating Officer of Life Biosciences.In this episode, we explore Michael's journey into the longevity space, the groundbreaking work happening at Life Biosciences, as well as their plans to launch human clinical trials for their epigenetic reprogramming asset within the next year.
loading
Comments